Literature DB >> 32952679

Cholesterol and Phospholipid Distribution Pattern in the Erythrocyte Membrane of Patients with Hepatitis C and Severe Fibrosis, before and after Treatment with Direct Antiviral Agents: A pilot Study.

Charalampos Papadopoulos1, Maria Panopoulou2, Theodora Mylopoulou2, Konstantinos Mimidis2, Ioannis Tentes1, Konstantinos Anagnostopoulos1.   

Abstract

Objectives: Hepatitis C virus requires and induces changes in liver lipidome for its life cycle. In addition, alterations in plasma and erythrocyte lipidome are observed during a range of chronic liver diseases.
Methods: A total of six subjects (three males and three females) were included in our study. All subjects were HCV positive according to virus RNA detection. Erythrocyte ghosts were prepared from blood and collected upon diagnosis and also at the end of the treatment with Direct Antiviral Agents (DAA). Lipids were extracted from the erythrocyte ghosts, and cholesterol and phospholipids were analyzed by thin layer chromatography. A semi-quantitative estimation of cholesterol (CHOL), phosphatidylethanolamine (PE), phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylcholine (PC) and sphingomyelin (SM) was performed by densitometric analysis of the chromatographs.
Results: After the antiviral treatment, PE percentage decreased, whereas the PC/PE and CHOL/PE ratio increased significantly. There were also other weaker differences for CHOL, PI, PS, PC and SM. Before DAA there was a very weak correlation between ALT and PC/PE ratio. In contrast, there was a steep negative correlation between these two parameters after DAA.
Conclusion: Red blood cell lipid composition and especially the PC/PE ratio could be a candidate real time biological marker for inflammation resolution during hepatitis C treatment.

Entities:  

Year:  2020        PMID: 32952679      PMCID: PMC7482690          DOI: 10.26574/maedica.2020.15.2.162

Source DB:  PubMed          Journal:  Maedica (Bucur)        ISSN: 1841-9038


  26 in total

1.  Marked elevation of erythrocyte ribavirin levels in interferon and ribavirin-induced anemia.

Authors:  Masato Homma; Yasushi Matsuzaki; Yoichi Inoue; Minoru Shibata; Keiji Mitamura; Naomi Tanaka; Yukinao Kohda
Journal:  Clin Gastroenterol Hepatol       Date:  2004-04       Impact factor: 11.382

2.  Evaluation of the Bayesian and Maximum Likelihood Approaches in Analyzing Structural Equation Models with Small Sample Sizes.

Authors:  Sik-Yum Lee; Xin-Yuan Song
Journal:  Multivariate Behav Res       Date:  2004-10-01       Impact factor: 5.923

3.  Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage.

Authors:  L De Franceschi; G Fattovich; F Turrini; K Ayi; C Brugnara; F Manzato; F Noventa; A M Stanzial; P Solero; R Corrocher
Journal:  Hepatology       Date:  2000-04       Impact factor: 17.425

4.  The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis.

Authors:  Zhaoyu Li; Luis B Agellon; Theresa M Allen; Masato Umeda; Larry Jewell; Andrew Mason; Dennis E Vance
Journal:  Cell Metab       Date:  2006-05       Impact factor: 27.287

5.  Elevated plasma sphingomyelin (d18:1/22:0) is closely related to hepatic steatosis in patients with chronic hepatitis C virus infection.

Authors:  J-F Li; F Qu; S-J Zheng; H-L Wu; M Liu; S Liu; Y Ren; F Ren; Y Chen; Z-P Duan; J-L Zhang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-05-09       Impact factor: 3.267

6.  Nutritional status in cirrhotic patients.

Authors:  Adriana Teiusanu; Mihai Andrei; Tudor Arbanas; Tudor Nicolaie; Mircea Diculescu
Journal:  Maedica (Buchar)       Date:  2012-12

7.  Erythrocyte lipid composition and sodium transport in human liver disease.

Authors:  J S Owen; N McIntyre
Journal:  Biochim Biophys Acta       Date:  1978-06-16

8.  Phosphatidylethanolamine Is a Key Regulator of Membrane Fluidity in Eukaryotic Cells.

Authors:  Rosie Dawaliby; Cataldo Trubbia; Cédric Delporte; Caroline Noyon; Jean-Marie Ruysschaert; Pierre Van Antwerpen; Cédric Govaerts
Journal:  J Biol Chem       Date:  2015-12-09       Impact factor: 5.157

9.  Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response.

Authors:  Christoph Welsch; Mira Efinger; Michael von Wagner; Eva Herrmann; Stefan Zeuzem; Tania M Welzel; Christian M Lange
Journal:  PLoS One       Date:  2017-02-14       Impact factor: 3.240

10.  Temporal proteome and lipidome profiles reveal hepatitis C virus-associated reprogramming of hepatocellular metabolism and bioenergetics.

Authors:  Deborah L Diamond; Andrew J Syder; Jon M Jacobs; Christina M Sorensen; Kathie-Anne Walters; Sean C Proll; Jason E McDermott; Marina A Gritsenko; Qibin Zhang; Rui Zhao; Thomas O Metz; David G Camp; Katrina M Waters; Richard D Smith; Charles M Rice; Michael G Katze
Journal:  PLoS Pathog       Date:  2010-01-08       Impact factor: 6.823

View more
  2 in total

1.  Red Blood Cell Dysfunction in Non-Alcoholic Fatty Liver Disease: Marker and Mediator of Molecular Mechanisms.

Authors:  Charalampos Papadopoulos; Ioannis Tentes; Konstantinos Anagnostopoulos
Journal:  Maedica (Bucur)       Date:  2020-12

2.  Lipidomics Indicates the Hepatotoxicity Effects of EtOAc Extract of Rhizoma Paridis.

Authors:  Chaofeng Li; Mingshuang Wang; Tingting Fu; Zhiqi Li; Yang Chen; Tao He; Dan Feng; Zhaoyi Wang; Qiqi Fan; Meilin Chen; Honggui Zhang; Ruichao Lin; Chongjun Zhao
Journal:  Front Pharmacol       Date:  2022-02-08       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.